US › Healthcare

Oruka Therapeutics, Inc. (ORKA)

US · Healthcare · Biotechnology

$98.13+3.52%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-31.8M
Profit YoY
-51.5%
EPS
$-0.48
EPS estimate
$-0.54

EPS came in at -0.48 against a street estimate of -0.54 — a beat of 11.1%.

Key statistics

Market cap
$5.82B
Forward P/E
0.0
P/B
12.02
Book value
$9.64
EPS (TTM)
$-1.93
52-week high
$99.00
52-week low
$12.84
50-day MA
$77.96
200-day MA
$49.02

Analyst view

Analysts rate Oruka Therapeutics, Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $148.17.

Shareholding

Insiders
1.23%
Institutions
95.50%

Largest institutional holders

FundStake
FMR Inc12.32%
VR Adviser, LLC6.88%
Fairmount Funds Management LLC6.14%
BlackRock Inc5.85%
Viking Global Investors LP4.42%
Vanguard Group Inc4.07%
Paradigm Biocapital Advisors LP3.85%
RTW INVESTMENTS, LLC3.41%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Oruka Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.